2024-2025 is an optimistic deadline for Miramistin to enter European markets. Evgeny Gorokhov, a member of the Board of Directors of Infamed K, told about this in an interview with the editorial board of Made in Russia.

According to Gorokhov, the company has been trying to enter the foreign market since 2012.

"The most difficult path was chosen, according to the "German" scheme. You need to understand that in Europe there are conditionally three medical clusters in which you can pass certification. And if you pass it along, relatively speaking, the "eastern" route, that is, in one of the countries of the former social bloc, then in France and Germany, where there is the most solvent demand, no one will want to work with your product," explained Evgeny Gorokhov.

To exclude such situations, Infamed K in Austria, in accordance with the requirements of the Austrian regulator, goes through the same stages that were completed in the 1990s in Russia. According to Gorokhov, the company is interested in the countries of Western Europe. In addition, it is much easier to enter the market of Southern and Eastern Europe with an Austrian license.

"All laboratory and preclinical tests lasted about 5 years. In parallel, we have re-synthesized a pharmaceutical substance at a contract production facility in Italy. Then we received permission to conduct clinical trials with the participation of patients. Now this stage has been completed, but we are not satisfied with the result and in this regard we plan to conduct the third phase of the "clinic". It will probably start this fall," Gorokhov added.

You can read the full version of the interview with Evgeny Gorokhov, a member of the Board of Directors of Infamed K, here.

Read other interesting news in ourTelegram channel

Author: Anton Yakovlev

Made in Russia // Made in Russia

#made by Russia